Evidence map›Paper›PMID 37809172›Full record

ArticleCureus2023

Allopurinol-Induced Uncommon Dermatological Emergency of Toxic Epidermal Necrolysis (TEN).

Umesh Kumar Pabani, Zahid Khan, Layla Ali, Shuheda K Shah, Jebriel Ali Khan

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Umesh Kumar PabaniInternal Medicine, Mid and South Essex NHS Foundation Trust, Southend-on-Sea, GBR.
Zahid KhanAcute Medicine, Mid and South Essex NHS Foundation Trust, Southend-on-Sea, GBR.
Layla AliInternal Medicine, Southend University Hospital, Southend-on-Sea, GBR.
Shuheda K ShahGeneral Medicine, Mid and South Essex NHS Foundation Trust, Southend-on-Sea, GBR.
Jebriel Ali KhanRespiratory Medicine, Great Western Hospital, Swindon, GBR.
Barking, Havering And Redbridge University Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxic epidermal necrolysis (TEN) is a life-threatening, blistering dermatitis. It is characterized by fever and the development of mucocutaneous lesions, which lead to necrosis and sloughing of the epidermis. It is commonly triggered by medications and infections. We present the case of a 75-year-old male who presented to the hospital with a fever and widespread exfoliating skin rash involving 41% of his body surface area (BSA). He has a past medical history of gout, hypertension, asthma, and depression. He was recently started on allopurinol by his general practitioner (GP) for hyperuricemia. The condition also involved oral, eye, and pharynx mucosae. He was diagnosed with toxic epidermal necrolysis and was managed with intravenous (IV) hydrocortisone, steroid and antibiotic eye drops, and steroid and antibiotic topical creams. Due to the weak available evidence supporting the use of ciclosporin and intravenous immunoglobulins, this patient was managed with steroid use only. His rash initially worsened, but ultimately, he made a full recovery without any sequelae. The patient was reviewed in the dermatology clinic four weeks post-discharge, and he did not have any residual disease.

Indexed as

adverse cutaneous drug reactionallopurinol-induced tenantibiotics creamcutaneous adverse drug reactiondrug-induced tenmedication-induced tensevere cutaneous adverse drug reactionssystemic steroidstoxic epidermal necrolysis (ten)

Identifiers

PMID37809172
PMCPMC10558959
OpenAlexW4386520748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.